FDA approves CRENESSITY: A breakthrough treatment from Neurocrine Biosciences for classic congenital adrenal hyperplasia

Neurocrine Biosciences has announced US Food and Drug Administration (FDA) approval of CRENESSITY, marking a significant milestone in the treatment of classic congenital adrenal hyperplasia ... Read More